Kinetics and Extent of T Cell Activation as Measured with the Calcium Signal

By Christoph Wülfing,* Joshua D. Rabinowitz,† Craig Beeson,‡ Michael D. Sjaastad,§ Harden M. McConnell,‡ and Mark M. Davis§

From the *Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305-5402; †Department of Chemistry, Stanford University School of Medicine, Stanford, California 94305-5080; and the §Howard Hughes Medical Institute, Beckman Center, Stanford University, Stanford, California 94305-5428

Summary

We have characterized the calcium response of a peptide-major histocompatibility complex (MHC)-specific CD4 T lymphocyte line at the single cell level using a variety of ligands, alone and in combination. We are able to distinguish four general patterns of intracellular calcium elevation, with only the most robust correlating with T cell proliferation. Whereas all three antagonist peptides tested reduce the calcium response to an agonist ligand, two give very different calcium release patterns and the third gives none at all, arguing that (a) antagonism does not require calcium release and (b) it involves interactions that are more T cell receptor proximal. We have also measured the time between the first T cell–antigen-presenting cell contact and the onset of the calcium signal. The duration of this delay correlates with the strength of the stimulus, with stronger stimuli giving a more rapid response. The dose dependence of this delay suggests that the rate-limiting step in triggering the calcium response is not the clustering of peptide–MHC complexes on the cell surface but more likely involves the accumulation of some intracellular molecule or complex with a half-life of a few minutes.

The binding of T cell receptor to a specific MHC–peptide complex is the critical step in T cell activation as it initiates the intracellular signaling cascade in the T cell (reviewed in reference 1). The first known step in this cascade is the tyrosine phosphorylation of CD3 chains (2, 3). Among other downstream events, these phosphorylations lead to an increase in the level of intracellular calcium (reviewed in reference 4). Initially, calcium is released from intracellular stores, followed by an influx of exogenous calcium through calcium-specific channels in the cell membrane (5, 6). The direct coupling of CD3 phosphorylation to calcium mobilization has been demonstrated by reconstitution of this signaling pathway in COS-1 cells (7).

One major effect of the elevated calcium levels is the activation of calcineurin. This leads to the translocation of the cytoplasmic component of the T cell–specific transcription factor NF-AT1 to the nucleus and the initiation of transcription (8). The shape and mobility of T cells are also regulated by calcium (9, 10). Changes in intracellular calcium levels can be observed directly at the single cell level using ratiometric fluorescent dyes (9–14). While there is general agreement that the calcium signal is a specific consequence of T cell activation, the form and dose response of the signal remain controversial.

Apart from the calcium signal, other signaling pathways are activated following the engagement of the TCR. These include the pathway leading to the activation of the ERK kinases of the MAP kinase family via ras and raf (reviewed in reference 1). In addition, other T cell surface receptors such as B7 and cytokine receptors have been demonstrated to contribute to T cell activation (15, 16).

In addition to the TCR, the T cell coreceptor CD4 also binds to MHC class II, although its binding is not antigen specific. The cytoplasmic tail of CD4 can associate with the tyrosine kinase lck and recruit lck to the TCR complex (17). But even when the lck kinase domain is inactive (18) or in the absence of the CD4–lck association (19, 20) CD4 can contribute to the activation of T cells.

Altering antigenic peptides without decreasing their ability to bind to the MHC can have dramatic effects on T cell responses (reviewed in references 21–24). Some altered peptides elicit only a subset of the responses induced by the original peptide and thus have been labeled partial agonists (25, 26). Some inhibit an otherwise productive response to the original peptide and can thus be considered antagonists.

1Abbreviations used in this paper: CHO, Chinese hamster ovary; MCC, moth cytochrome C; NF-AT, nuclear factor of activated T cell.
(27). Such antagonist peptides alone trigger some biochemical events in T cells, resulting in partial phosphorylation of the CD3-ζ chain (28–32). It has been found that the biological effect of a series of altered peptides correlates, with very few exceptions, with the half-life of the corresponding MHC-peptide-TCR complexes in vitro (28–30). Such a correlation has also been suggested based on work with agonists (33) and on theoretical grounds (34, 35).

In a previous study (36), we correlated different biological responses elicited by a set of altered peptides. This has been done in the presence or absence of blocking antibodies against CD4. We find that the different biological responses can be organized into a hierarchy of signaling, from ones elicited by most altered peptides to ones elicited only by the wild-type peptide and variants of it with minimal alterations. In this study, we characterize the form, frequency, and time course of the calcium response to different peptides at the single cell level. We show that the calcium signal reflects the postulated hierarchy of signaling and is predictive of subsequent T cell proliferation. In addition, we measure a delay between T cell-APC contact and the onset of the calcium signal, which is dependent on the strength of the activating stimulus. We suggest a model to explain this delay in the onset of the calcium signal in which the rate-limiting step in triggering the calcium response involves the accumulation of an intracellular signaling molecule with a half-life of a few minutes.

Materials and Methods

Peptides and Antibodies. Peptides were synthesized with standard Fmoc chemistry and purified by reverse phase HPLC. Anti-CD4 antibody GK1.5 was purchased from Becton-Dickinson (Mountain View, CA).

Cell Line. The moth cytochrome c (MCC)-specific 5C.C7 T cells were derived from the 5C.C7 TCR-transgenic mouse (37, 38). Spleen cells were primed with 10 μM MCC peptide and expanded for 8 d in IL-2 containing medium. The T cells (1 × 10⁶ cells/ml) were restimulated with irradiated (3,000 rads) B10.BR spleen cells and 10 μM MCC peptide. After 10 d of culture and expansion in the presence of IL-2, CD4⁺ cells were sorted by flow cytometry and restimulated in 10-d intervals.

Calcium Imaging. For calcium imaging, 5C.C7 T cells were loaded for 30 min at room temperature with 2 μM Fura-2 in 10% FCS in PBS with 1 mM CaCl₂ and 0.5 mM MgCl₂. Chinese hamster ovary (CHO) cells transfected with I-Ek were grown in 8-well coverslips (Nunc, Naperville, IL) and peptide loaded with 25 μM peptide for 4–16 h. Peptide loading efficiency throughout this time range was almost constant. After washing unbound peptide away with 5% FCS in PBS with 1 mM CaCl₂ and 0.5 mM MgCl₂, Fura-2-loaded T cells were added onto a patch of confluent CHO cells on the microscope stage to start the experiment. Intracellular calcium in T cells was determined using C-Imaging-1280 System hardware and the Simca Quantitative Fluorescence Analysis software package; both from Compix, Inc., Imaging Systems (Mars, PA). The imaging system was coupled to a Nikon Diaphot 300 inverted microscope, which was equipped with the epifluorescence attachment and a 75W Xeon arc lamp. Alternate excitation of Fura-2-loaded T cells at 340 and 380 nm was achieved using a Ludl high speed dual filter wheel (Ludl Electronic Products, Hawthorne, NY) controlled by the Simca software. Images were collected with a CCD camera (Dage-MTI CCD72) in combination with a SuperGen II intensifier, (Dage-MTI, Michigan City, IN) to amplify fluorescence. Analysis of intracellular calcium and the generation of figures was achieved with the Simca software package. Per run, 30 to 40 cells were picked at random and analyzed. Data of different runs were pooled. For the figures, data of different experiments in which the topic of the figure was studied in direct comparison of the conditions under question was pooled. Only the I025 titration series (part of Figs. 2 and 3) shows a single representative experiment. The fluorescence of the Fura-2–loaded T cell is only visible when the T cell is right on top of the CHO layer. Because the T cells are added to the chamber from the top, their appearance in the fluorescence image is taken as the time of first contact.

Kinetic Model. One signaling component, A, will be converted into another, B, with the rate constant k₁ triggered by the MHC-peptide-TCR contact. Both the concentration of peptide and the type of peptide, as described by the half-life of its MHC-peptide-TCR complex (28–30), influence k₁. Because partial agonist and antagonist peptides give a qualitatively different signal the effect on k₁ of changing the peptide type shall be much more drastic than changing the peptide concentration. Using a first order kinetics, and assuming that the concentration of B before the MHC-peptide-TCR contact is 0, the concentration of A is A₀. B would form over time with B(t) = A₀ × (1 − e⁻ᵏ₁t). We now suggest that a minimal amount of B has to form to propagate the signal, the trigger concentration Bₜ. The time tₛ that is needed to accumulate Bₜ is given by: tₛ = −k₁⁻¹ × ln(1 − Bₜ/A₀). From this formula it can be seen that the smaller k₁ is, the longer it will take to reach the trigger concentration. However, one problem with this simple description is that even very weak signals would trigger activation, given enough time. As we do not observe this we suggest that, either directly or indirectly, B returns back to A with the rate constant k₋₁ that for reasons of simplicity is assumed to be independent of the MHC-peptide-TCR contact. The rate of the formation of B then becomes B(t) = A₀ × (1 + k₋₁/k₁) × (1 − e⁻ᵏ₁t). Using this model, the maximum amount of B that is formed depends on the ratio of k₋₁/k₁. The smaller k₁ is relative to k₋₁, the smaller this maximum level will be. Using weak activation conditions, as very low concentrations of peptide or antagonist peptides by themselves, the trigger level is never reached.

Results

Different Stimuli Elicit Distinct Calcium Signals. A number of TCRs have been characterized that recognize the MCC peptide (88–103) restricted by I-Ek. Different variants of the peptide have been studied in several respects: (a) peptide binding to I-Ek (39), (b) kinetic rate constants for the binding of the peptide–MHC to the 2B4 and 5C.C7 TCR (30, 33, 40), (c) ability to stimulate IL-3 production, proliferation, and acid release in a 5C.C7 line (36, 39). Taking advantage of this extensive data set, we chose one of the best studied of these models, 5C.C7, to characterize the changes in the concentration of intracellular calcium after T cell activation in response to different stimuli. The particular 5C.C7 line we chose to study is derived from the CD4⁺ cells of the spleen of 5C.C7 TCR transgenic mice (37; Fazekas de St. Groth, B., and M.M. Davis, unpublished research).
results. It is maintained by periodic restimulation with antigen (36). As an APC, we have used CHO cells transfected with I-Ek, which can effectively stimulate a variety of T cells (41, 42).

The calcium response to well-characterized peptides in the MHC family was studied (Fig. 1). For all of them the anchor residues to the MHC are unchanged, and thus binding to I-Ek is very similar (39). Two of the three major TCR contact residues, positions 99 and 102 (39, 43), were changed more or less drastically in different peptides.

The changes in the level of intracellular calcium during T cell stimulation were recorded from single cells for 16-18 min, using the calcium-sensitive fluorescent dye, Fura-2 (45). In a single cell assay differences in the response within a population of responders can be resolved, allowing more extensive analysis. This proved to be crucial in particular for the characterization of different types of calcium signals. The experiments were done at 25°C. Relative differences in type, frequency, and timing of the calcium signal are the same as at 37°C, but the movement of the cells after activation is considerably less (Wülfing, C., and M.M. Davis, data not shown). This reduction in cell movement at 25°C allows a more precise determination of the form of the calcium signal. In our assays, we first recorded the time between APC–T cell contact and the onset of the calcium signal. Second, the form of the calcium signal after the onset varies. Using the MCC peptide, more than 95% of the cells respond with full signal, as shown in Fig. 2 and described in Table 1. With the altered peptides, we find three qualitatively different variants of the full signal, a reduced, partial, and transient signal (Fig. 2; Table 1). These describe the increasingly weaker calcium responses that we see and have predictive value.

**Figure 1.** Peptides used. At the top of the figure the sequence of the MCC peptide is shown. The main TCR contact residues are indicated with an upward arrow, the main MHC contact residues with a downward arrow. Numbers indicate amino acid residue numbers of the MCC protein. Underneath, the altered peptides are listed. Only the residues that deviate from the wild-type sequence are shown. The mutation at the position 93 has no effect on either MHC binding or T cell stimulation (39, 44).

### Table 1: Types of Calcium Signals

| Type       | Onset          | Form of the signal over time                           |
|------------|----------------|--------------------------------------------------------|
| Full       | Singular       | Sustained high                                        |
| Reduced    | Singular       | Declining or fluctuating above resting calcium level   |
| Partial    | Multiple       | Fluctuating down to resting calcium level              |
| Transient  | Singular       | Rapid return to resting calcium level                  |

Four general types of calcium signals are observed according to the number of rapid rises from baseline, onset, and the form of the calcium signal after the initial rise, form of the signal over time. Corresponding single cell calcium traces are shown in Fig. 2.
Figure 2. Types of calcium signals. For each signaling type, as indicated by the name at the top left and defined in Table 1, two examples are given that each consist of a pair of panels. In the top panel (single trace image), the ratio of the emission intensities at 340 nm over 380 nm is shown. This is proportional to the intracellular calcium level. In the bottom panel (double trace image), separate emission intensities at 340 nm and 380 nm are shown. The emission intensity at 380 nm is stronger than the emission intensity at 340 nm at the beginning of the recording and can thus be identified. Occasional strong fluctuations at the beginning of the images in both wavelengths and the ratio (e.g., left partial panel) are explained by out of focus fluorescence while the T cell settles into the plane of focus of the objective. It can be identified in the single wavelength images by very low intensities followed by a parallel increase in both wavelength. The individual wavelength traces help in the distinction between full and reduced signals. In a reduced signal the 380 nm trace does not fall close to (right panel) or does not stay close to (left panel) baseline after activation.
MCC and 102S giving identical dose-response curves. This is reflected in a high calcium signal responder frequency for both. On the other hand, the strongly reduced or absent calcium signal for 102G and 99R correlates with the lack of an acidification response. Because acidification is measured in a bulk assay, the small degree of activation measured in a single cell calcium assay, e.g., for the peptide 102G, might not be detectable above background in the acid release assay. Thus, only a full calcium signal correlates with a proliferation response. In contrast, acid release correlates with a high frequency response, irrespective of signal type.

The Time Between T Cell–APC Contact and Onset of the Calcium Signal Is Determined by the Strength of the Activating Stimulus.

The design of our calcium assay allows us to determine the precise time between first APC–T cell contact and the rise in intracellular calcium. We refer to this as the onset delay. This onset delay is composed of two components. Even under the strongest activation conditions, there is a minimal time delay of ~1 min for the activation of the first T cells. Using weaker stimuli, we find that the onset delay increases as the stimulus gets weaker (Fig. 4). This delay is seen both in the time it takes to activate the first cell, as well as in the average onset time of the T cells in a given experiment.

For the MCC peptide, the onset delay is the shortest with an average of about 3 min and stays unchanged even at 25 nM MCC (a dilution of 1:1,000 into the neutral peptide 93E99T102A) (Fig. 4). 25 μM 102S or 102S diluted only 1:10 into the neutral peptide (2.5 μM) shows an onset delay that is similar to MCC. However, at lower concentrations there is a significant increase in the onset delay with a shift from about 3 min to 6 min for 25 nM 102S (1:1,000 dilution into the neutral peptide) (Fig. 4). Furthermore, the antagonist peptide, 102G, gives an onset delay of 10 min, in combination with a strongly reduced responder frequency. In general, a full calcium signal shows a rapid onset, a slightly reduced calcium signal shows a small onset delay.

**Figure 3.** Frequency and type of the calcium response to MCC and altered peptides. The percentage of each signal type for different peptides at different dilutions. Signal types are given in the legend. Peptide names are given in the first row at the bottom of each column. 99T102A stands for the peptide 93E99T102A. When MCC or 102S has been diluted into the neutral peptide 93E99T102A, the concentration of MCC or 102S is given in the bottom row. The total peptide concentration is always 25 μM.

**Table 2.** Comparison of Calcium Data with Other Biological Assays

| Peptide | Acid release 10 μM | Acid release 10 nM | Calcium signal (percentage/quality/onset) 25 μM | Calcium signal (percentage/quality/onset) 25 nM | Proliferation 10 μM | Proliferation 10 nM |
|---------|-------------------|-------------------|---------------------------------|---------------------------------|-----------------|-----------------|
| MCC | + | + | 100%/full/immediate | 100%/full/immediate | + | + |
| MCC + anti-CD4 | + | ND | N D | 100%/reduced/immediate | 100%/reduced/delayed | + | + |
| 102S | + | + | 100%/reduced/immediate | 100%/reduced/delayed | + | ± |
| 102S + anti-CD4 | + | ND | N D | 100%/reduced/delayed | N D | – | – |
| 102G | – | – | 15%/reduced/delayed | N D | – | – |
| 99R | – | – | 0% | N D | – | N D |
| Neutral peptide | – | – | 0% | N D | – | N D |
| MCC in 102G | ND | ND | 80%/reduced/delayed | 80%/reduced/delayed | – | – |
| MCC in 99R | ± | ± | 80%/reduced/delayed | 80%/reduced/delayed | – | – |

The proliferation and acidification data are taken from Rabinowitz et al. (36) and are compared with the calcium data of this study. Peptides are given in the first column. In the bottom part of the table where two peptides are given, the first has been diluted into the second 1:1,000. + anti CD4 denotes the presence of 100 ng/ml of the anti-CD4 antibody GK1.5. Peptides have been used at the concentration that is indicated at the top of each column. The small peptide concentration in the second calcium data column has been achieved by a 1:1,000 dilution of the peptides into the neutral peptide, resulting in 25 nM concentration. For the acidification and proliferation assays, a plus signifies a strong response, plus minus signifies weak response, and minus signifies no detectable response. For the calcium assays three readouts are compiled: percentage signifies the percentage of responding cells, 100% signifies virtually all cells respond, 0% signifies no responders. Quality indicates the types of calcium signal: <10% reduced or nil signals are seen or >10% of reduced or nil signals, as indicated by full or reduced. Onset gives the onset time of the calcium signal: >50% of the cells activate within the first 4 min or not, as indicated by immediate versus delayed.
Kinetics and Extent of T Cell Activation

1820

delay, and a strongly reduced calcium signal displays a large
onset delay. Thus, this delay in T cell activation seems to
be an integral part of the response to different ligands.

Blocking CD4 and Antagonism. We also studied the ef-
effect of blocking CD4 coreceptor engagement on the 102S
and MCC calcium response. In the presence of 100 ng/ml
of the anti-CD4 antibody GK1.5, the calcium signal in-
duced by 25 nM MCC or 102S is reduced with respect to
the frequency and type of signal (Fig. 5A). The onset is not
significantly delayed (Fig. 5B). This suggests that CD4
plays a role predominantly after the onset of the calcium
signal. The inhibition of the calcium signal by CD4 corre-
lates with the data of Rabinowitz et al. (36), who have
shown that GK1.5 blocks proliferation in response to
MCC and 102S.

The peptides 99R and 102G have been shown to act as
antagonists in cytokine secretion and proliferation assays
(Reay et al., in preparation; 36). Furthermore, the partial
agonist 102S can be changed into an antagonist in the pres-
ence of 100 ng/ml of the anti-CD4 antibody (36). To as-
se ss the effect of antagonists on the calcium response, the
MCC peptide was serially diluted into the three different
antagonist conditions. For a 1:10,000 dilution of MCC into
102S/GK1.5, resulting in 2.5 nM MCC concentration,
10% of the cells do not respond at all, and 30% respond
with a reduced calcium signal (Fig. 6A). This is essen-
tially the same signal seen with the 102S peptide and GK1.5
alone without any MCC (see Fig. 5). A 1:10,000 dilution
of the MCC into 99R and 102G leads to a reduction in the
frequency of responding cells to less than 40%, and almost
all calcium signals are partial (Fig. 6B). Thus, the normal
MCC calcium response can be efficiently antagonized un-
der limiting activation conditions. In all three cases, the
antagonist effect depends strongly on the concentration of
the agonist, as MCC diluted to 1:1,000 shows only a small an-
tagonistic effect, as judged by the slight reduction in type
and frequency of the calcium signal (Fig. 6A). Interest-
ingly, however, all three antagonist conditions delay the
onset of the calcium signal, ranging from slightly (about 1
min larger) to more than twice as long (Fig. 6B).

Discussion

Intracellular Calcium Elevation and T Cell Responsiveness.
We show here that the form of the intracellular calcium
traces can vary widely depending on the activation condi-
tions. Under fully activating conditions, the calcium trace
shows a rapid rise followed by a smooth plateau. Under
suboptimal activation conditions, the intracellular calcium
concentration fluctuates considerably more after the initial
rise (Fig. 2). Other investigators have described single cell
calcium traces for peptide-dependent T cell activation at high
concentrations of agonist peptide or with cross-linking anti-
CD3 antibody. They found either oscillations (9, 11, 14, 46)
or smooth calcium traces (47), or a combination of both
forms (12). While these different results may be due to dif-

Figure 4. Onset of the calcium response to MCC and altered peptides.
Cumulative representation of percent of cells activated (irrespective of the
type of signal) during a specific onset time interval. Numbers on the time
axis indicate end time point of the interval, i.e., cells activating within 2
min after initial APC contact are shown at time point 2. Peptide name is
given in the legend. When MCC or 102S have been diluted into the
neutral peptide 93E99T102A, the concentration of MCC or 102S is also
given in the legend. Total peptide concentration is always 25 μM.

Figure 5. Effect of anti-CD4 antibody GK1.5 on the type and onset of
the calcium signals. (A) Percentages of each signal type (as explained in
Fig. 3). MCC or 102S were diluted 1:1,000 into the neutral peptide
MCC93E99T102A, resulting in 25 nM concentration. The type of pep-
tide and the absence or presence of the antibody GK1.5 are indicated un-
der the columns. The antibody concentration is 100 ng/ml. (B) Cumula-
tive representation of % cells activated (irrespective of the type of signal)
during a specific onset time interval. Time axis as in Fig. 4B. Conditions
are as in A and are indicated in the header.


Figure 6. Antagonism. (A) Percentages of each signal type (as explained in Fig. 3) for dilution of MCC into different peptides as given below the bars. 99T 102A indicates the peptide 93E99T102A. 102S/CD4 indicates 102S in the presence of 100 ng/ml anti-CD4 antibody GK1.5. The left five bars show, as indicated on the top, the data for the 1:1,000 dilutions of MCC, resulting in 25 nM MCC concentration. The right five bars show the data for the 1:10,000 dilutions, resulting in 2.5 nM MCC concentration. (B) Cumulative representation of percent of cells activated (irrespective of the type of signal) during a specific onset time interval for the 1:1,000 dilutions of MCC into antagonist peptides, as indicated in the header. Time axis as in Fig. 4 B.

different ligands used, an alternative explanation relates to the degree of transformation of the T cells. When we compare calcium traces from 5C.C7 naive cells, T cells primed once, multiply primed T cells, i.e., the line used in this publication, and an restimulation-independent 5C.C7 T cell line, we find that the incidence of oscillations increases with the degree of transformation of the T cells (Wülfing, C., and M. M. Davis, in preparation). Consistent with this, the studies that show the most oscillatory T cell calcium traces (14, 46) both used hybridomas.

In the system used here, we find that the elevation of intracellular calcium varies from the full response to various reduced or oscillatory patterns and that this correlates with other bioassays as summarized in Table 2. A positive result in the acidification assay is always accompanied by some calcium signaling, whereas a proliferative response correlates with a full calcium signal in most of the cells. Even a small disturbance of the full signal, such as a delayed onset or a response from less than 100% of the T cells, correlates with an inability of the stimulus to induce proliferation of the whole population. This suggests that the need for paracrine help may require the proliferation of the large majority of the individual cells in a population. Furthermore, other intracellular signaling pathways that are necessary for full T cell activation may be activated independent of the calcium signal to some extent. Nevertheless, the importance of a sustained calcium signal has been shown by Timmerman et al. (48), who have demonstrated that only a sustained calcium elevation signal is able to keep NF-AT c in the nucleus. Similarly, Negulescu et al. (46) have shown that a sustained elevation of the intracellular calcium concentration is necessary for the activation of an IL-2 promoter reporter construct. From the data of Karttunen and Shastri (49) and Valitutti et al. (50), it also appears that a full calcium stimulus must be maintained for at least 30–60 min to induce an irreversible commitment to T cell activation, particularly at lower peptide concentrations. Given the importance of the sustained phase of the calcium signal, a small reduction might contribute significantly to a severe reduction in proliferation.

During activation, the T cell receives a wide variety of signals through a large number of individual receptors that have to be integrated within the signaling pathway to allow the cell to decide whether to proliferate or not. Our data allows us to estimate to what extent the calcium signal is already integrated. The pattern of elevation of the intracellular calcium elicited by different peptides is not only quantitatively different, but qualitatively as well. Antagonism is more effective at a higher dilution of the agonist peptides into the antagonist. A blocking anti-CD4 antibody reduces the calcium signal. These three observations suggest that a T cell has counted and qualified the different signals through a large number of individual receptors that have to be integrated within the signaling pathway to allow the cell to decide whether to proliferate or not. Our data allows us to estimate to what extent the calcium signal is already integrated. The pattern of elevation of the intracellular calcium elicited by different peptides is not only quantitatively different, but qualitatively as well. Antagonism is more effective at a higher dilution of the agonist peptides into the antagonist. A blocking anti-CD4 antibody reduces the calcium signal. These three observations suggest that a T cell has counted and qualified the different signals through TCR and CD4 before the elevation of the intracellular calcium concentration. In the process of signal integration, the calcium signal thus seems to be much closer to the final proliferation decision than to the events elicited directly by the single engaged receptors.

Altered Ligands. With respect to TCR antagonist ligands, recently Sloan-Lancaster et al. (47) have shown that several antagonist ligands can induce weak calcium fluxes and suggest that this might be part of an antagonist signal. Our own data shows that whereas two different antagonist stimuli (102G alone or 102S + αCD4 antibody) generate detectable, but reduced calcium responses, one (99R) does not. This indicates that the mobilization of intracellular calcium is not necessary for antagonist peptide-MHC ligands to block a response. Thus, their primary effect may lie upstream in the T cell signaling process. Similarly, Windingen et al. (26) have described an antagonistic peptide that does not induce a calcium signal. Also consistent with a more TCR proximal effect of antagonism are the data of Sloan-Lancaster et al. (32) and Madrenas et al. (31) showing alterations in CD3-γ phosphorylation and subsequent ZAP-70 association as a consequence of antagonist ligand engagement.
Kinetics of the Onset Delay: Evidence for a Rate-limiting Step in Triggering a T Cell Calcium Signal with a Half-life of a Few Minutes. In this report, we determined the time between initial T cell–APC contact and onset of the calcium response. Comparing all activation conditions, we find that a minimal delay of 45 s is seen for the MCC peptide at high as well as low concentrations. Therefore, this initial delay must reflect events that are independent of the stimulus strength. Likely factors in this time frame are the time required for the establishment of cell–cell adhesion and for the transmission of intracellular signals from the membrane to the calcium stores.

Weak stimuli, such as partial agonist or antagonist peptides, result in an additional onset delay of up to 10 min. Recent studies have demonstrated that, in most cases, partial agonists and antagonists dissociate more rapidly from a given TCR than agonist ligands (28–30). Therefore, most altered peptide ligands should reach steady-state with respect to TCR binding more rapidly than agonist ligands. Furthermore, one characteristic of the onset delay is that large changes in the peptide dose result in only small changes in the activation time (Fig. 4). For example, going from 250 nM to 25 nM of the peptide 102S causes only a 40% increase in the onset time. If the formation of individual TCR–peptide–MHC pairs was the rate-limiting step in the induction of the calcium signal there would be, for concentrations of free MHC–peptide smaller than the concentration of free TCR, a linear increase in the onset time as the peptide concentration decreases. If the formation of TCR–peptide–MHC oligomers was critical there would be an even more dramatic increase in the onset time as a function of peptide concentration. Even more sophisticated models in which TCR–peptide–MHC mono- or oligomers need to interact for some minimal time in order for signaling to occur do not fit the observed peptide dependency of the onset delay (Kantor, R., C. Wülfing, and M.M. Davis, unpublished results). Thus, the increased onset time observed for weak stimuli does not appear to depend on some threshold level of TCR ligation or oligomerization. This is not to say that oligomerization does not occur or that the half-life of the TCR–peptide–MHC complex is not important, as other studies have shown that it is (30, 33), but that these factors may not be rate-limiting at the cellular level.

Instead, we suggest that the rate-limiting factor in this delay reflects intracellular reactions leading to the accumulation of signaling molecules. These reactions could involve a continuous competition between phosphorylation and dephosphorylation.
dephosphorylation, or between production or breakdown of other parts of the signaling machinery. We hypothesize that T cell activation shifts the balance of this equilibrium towards the accumulation of signaling molecules. A simple kinetic model based on a reaction scheme of this type agrees well with the onset delay that we observe (Fig. 7). The crucial feature of this scheme is that the turnover of the rate-limiting signaling intermediate is determined by an activation strength-dependent first-order forward and an activation strength independent first-order reverse reaction:

\[ k_1 \frac{A}{k - 1} B \]

The concentration over time of this signaling intermediate B is given by:

\[ B(t) = A_0 \times \left(1 + \frac{k_{-1}}{k_1}\right)^{-1} \times \left(1 - e^{k_1 t} + k_{-1} t\right) \]

The half-life of these reactions can be derived from our kinetic data. Under the very weak activation conditions of the antagonist 102G most calcium responses occur between 8–12 min. Because only a small percentage of the cells respond, the reaction leading to signaling must be nearly complete (i.e., at the new steady-state) before any responses occur. This is depicted in Fig. 7. Because the time to reach 95% of a new steady-state level of signaling intermediates is four times the half-time, 2 min is a good approximation for the half-time of the reaction towards the steady-state. At the same time, this is the lower limit for the half-times of the individual forward and reverse reactions of this steady-state. The half-times of this stimulus-independent reverse reaction and this forward reaction for 102G are a few minutes under the additional assumption that to trigger the calcium response the accumulation of the signaling intermediate has to be substantial but not complete (Fig. 7C). The half-times of the forward reaction for stronger activation conditions would be shorter. As these measurements were done at 25°C, one must also allow for a two to four times acceleration in this value at 37°C. In a broader biological picture, we thus suggest that the accumulation of a signaling intermediate triggers the calcium signal. This intermediate is continuously degraded with a half-time of a few minutes. Therefore, every T cell stimulus that results in calcium signaling has to produce this intermediate with a half-time of less than a few minutes.

Other early processes in T cell activation occur within a similar time frame. One example is \(\zeta\) chain phosphorylation (31, 32), which reaches steady-state within a few minutes for agonist signaling and within 2–10 min for antagonist signaling (32). Such a reaction could produce the postulated critical signaling intermediate.

We thank S. Palmieri from the Stanford Cell Science Imaging Facility for help and advice.

C. Wülfing was supported by an European Molecular Biology Organization long term fellowship, C. Beeson by the Cancer Research Institute, J.D. Rabinowitz by the Medical Scientist Training Program, and M.D. Sjaastad by the Howard Hughes Medical Institute. We also thank the Howard Hughes Medical Institute and the National Institutes of Health for supporting these studies.

Address correspondence to M.M. Davis, Department of Microbiology and Immunology, H.H.M.I., Beckman Center, Room B221, Stanford University, Stanford, California 94305-5428.

Received for publication 16 January 1997 and in revised form 11 March 1997.

References

1. Weiss, A., and D.R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. C. 676:263–274.
2. DeFranco, A.L. 1994. Signaling pathways activated by protein tyrosine phosphorylation in lymphocytes. Curr. Opin. Immunol. 6:364–371.
3. Sefton, B.M., and J.A. Taddie. 1994. Role of tyrosine kinases in lymphocyte activation. Curr. Opin. Immunol. 6:372–379.
4. Premack, B.A., and P. Gardner. 1992. Signal transduction by T-cell receptors: mobilization of Ca and regulation of Ca-dependent effector molecules. Annu. Rev. Immunol. 10:119–140.
5. Premack, B.A., and P. Gardner. 1994. Properties of Ca currents activated by T cell receptor signaling. Adv. Exp. Med. Biol. 365:91–102.
6. Chakrabarti, R., J.Y., Chang, and K.L. Erickson. 1995. T cell receptor-mediated Ca2+ signaling: release and influx are independent events linked to different Ca2+ entry pathways in the plasma membrane. J. Cell. Biol. 58:344–359.
7. Hall, C.G., J. Sancho, and C. Terhorst. 1993. Reconstitution of T cell receptor zeta-mediated calcium mobilization in nonlymphoid cells. Science (Wash. D.C.) 261:915–918.
8. Northrop, J.P., S.N. Ho, L. Chen, D.J. Thomas. L.A. Zimmerman, G.P. Nolan, A. Admon, and G.R. Crabtree. 1994. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature (Lond.). 369:497–502.
9. Donnadieu, E., G. Bismuth, and A. Trautmann. 1994. Antigen recognition by helper T cells elicits a sequence of distinct changes of their shape and intracellular calcium. Curr. Biol. 4:584–595.
10. Negulescu, P.A., T.B. Krasieva, A. Khan, H.H. Kerschbaum, and M.D. Cahalan. 1996. Polarity of T cell shape, motility, and sensitivity to antigen. Immunity. 4:421–430.
11. Donnadieu, E., D. Cefa, Y.P. Tan, G. Paresys, G. Bismuth, and A. Trautmann. 1992. Imaging early steps of human T cell activation by antigen-presenting cells. J. Immunol. 148:2643–2653.
12. Rones, J.S., and B. Bogen. 1994. Ca2+ mobilization in physiologically stimulated single T cells gradually increases with peptide concentration (analogue signaling). Eur. J. Immunol. 24:421–430.
17. Diez-Orejas, R., S. Balester, M.J. Feito, G. Ojeda, G. Criado, M. Ronda, P. Portoles, and J.M. Rojo. 1994. Genetic and immunochemical evidence for CD4-dependent association of p56ck with the alpha beta T-cell receptor (T CR): regulation of TCR-induced activation. EMBO J. (Eur. Mol. Biol. Organ.) 13:90–99.

18. Xu, H., and D.R. Littman. 1993. A kinase-independent function of Lck in potentiating antigen-specific T cell activation. Cell. 74:633–643.

19. Vignali, D.A., and J.L. Strominger. 1994. Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J. Exp. Med. 179:1945–1956.

20. Killeen, N., and D.R. Littman. 1993. Helper T-cell development in the absence of CD4–p56ck association. Nature (Lond.). 364:729–732.

21. Jameson, S.C., and M.J. Bevan. 1995. T cell receptor antagonists and partial agonists. Immunity. 2:1–11.

22. Madrenas, J., and R.N. Germain. 1996. Variant TCR ligands in the new molecular basis of antigen-dependent signal transduction and T cell activation. Semin. Immunol. 8:83–101.

23. Kersh, G.J., and P.M. Allen. 1996. Essential flexibility in the T-cell recognition of antigen. Nature (Lond.). 380:495–498.

24. Sloan-Lancaster, J., and P.M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1–27.

25. Evavold, B.D., and P.M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science (Wash. DC). 252:1308–1310.

26. Windhagen, A., C. Scholz, P. Hollborg, H. Fukaura, A. Sette, and D.A. Hafler. 1995. Modulation of cytotoxic T lymphocyte functions in human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:373–380.

27. De Magistris, M.T., J. Alexander, M. Coggeshall, A. Altman, F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:625–634.

28. al-Ramadi, B.K., M.T. Jelonek, L.F. Boyd, D.H. Margulies, and A.L. Bothwell. 1995. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J. Immunol. 155:662–673.

29. Alam, S.M., P.J. Travers, J.L. Wung, W. Nasholds, S. Redpath, S.C. Jameson, and N.R. Gascoigne. 1996. T-cell receptor affinity and thymocyte positive selection. Nature (Lond.). 381:616–620.

30. Lyons, D.S., S.A. Lieberman, J. Hampl, J.J. Boniface, P.A. Rey, Y.-h. Chien, L.J. Berg, and M.M. Davis. 1996. A T cell receptor binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity. 5:53–61.

31. Madrenas, J., R.L. Wange, J.L. Wang, N. Isakov, L.E. Samelson, and R.N. Germain. 1995. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science (Wash. DC). 267:515–518.

32. Sloan-Lancaster, J., A.S. Shaw, J.B. Rothbard, and P.M. Allen. 1994. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell. 79:913–922.

33. Matsui, K., J.J. Boniface, P. Steffner, P.A. Rey, and M.M. Davis. 1994. Kinetics of T-cell receptor binding to peptide/ I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. USA. 91:12862–12866.

34. McKeithan, T.W. 1995. Kinetic proofreading in T-cell receptor signal transduction. Proc. Natl. Acad. Sci. USA. 92:5042–5046.

35. Rabinowitz, J.D., C. Beeson, D.S. Lyons, M.M. Davis, and H.M. McConnell. 1996. Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. USA. 93:1401–1405.

36. Rabinowitz, J.D., C. Beeson, C. Wülfing, K. Tate, P.M. Allen, M.M. Davis, and H.M. McConnell. 1996. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity. 5:125–135.

37. Seder, R.A., W.E. Paul, M.M. Davis, and B. Fazekas de St. Groth. 1992. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J. Exp. Med. 176:1091–1098.

38. Fink, P.J., L.A. Matis, D.L. Mcelligott, M. Bookman, and S.M. Hedrick. 1986. Correlations between T-cell specificity and the structure of the antigen receptor. Nature (Lond.). 321:219–226.

39. Rey, P.A., R.M. Kantor, and M.M. Davis. 1994. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93–103). J. Immunol. 152:3946–3957.

40. Matsui, K., J.J. Boniface, P.A. Rey, H. Schild, B. Fazekas de St. Groth, and M.M. Davis. 1991. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science (Wash. DC). 254:1788–1791.

41. Sagerstrom, C.G., E.M. Kerr, J.P. Allison, and M.M. Davis. 1993. Activation and differentiation requirements of primary T cells in vitro. Proc. Natl. Acad. Sci. USA. 90:8987–8991.

42. Wettstein, D.A., J.J. Boniface, P.A. Rey, H. Schild, and M.M. Davis. 1991. Expression of a class II major histocompatibility complex (MCH) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH. J. Exp. Med. 174:219–228.

43. Jorgensen, J.L., U. Esser, B. Fazekas de St. Groth, P.A. Rey, and M.M. Davis. 1992. Mapping T-cell receptor–peptide contacts by variant peptide immunization of single-chain transgenic mice. Proc. Natl. Acad. Sci. USA. 89:355–224–330.

44. Rabinowitz, J.D., C. Beeson, D.S. Lyons, M.M. Davis, and H.M. McConnell. 1996. Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. USA. 93:1401–1405.

45. Tsien, R.Y. 1989. Fluorescent probes of cell signaling. Science (Wash. DC). 244:34–41.

46. Negulescu, P.A., N. Shastri, and M.D. Cahalan. 1994. Immunological evidence for CD4-dependent association of p56ck with the alpha beta T-cell receptor (T CR): regulation of TCR-induced activation. EMBO J. (Eur. Mol. Biol. Organ.) 13:90–99.

47. Sloan-Lancaster, J., T.H. Steinberg, and P.M. Allen. 1996. Essential flexibility in the T cell receptor signal transduction. Proc. Natl. Acad. Sci. USA. 93:5042–5046.

48. Evavold, B.D., and P.M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science (Wash. DC). 252:1308–1310.

49. Windhagen, A., C. Scholz, P. Hollborg, H. Fukaura, A. Sette, and D.A. Hafler. 1995. Modulation of cytotoxic T lymphocyte functions in human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:373–380.

50. De Magistris, M.T., J. Alexander, M. Coggeshall, A. Altman, F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:625–634.

51. Al-Ramadi, B.K., M.T. Jelonek, L.F. Boyd, D.H. Margulies, and A.L. Bothwell. 1995. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J. Immunol. 155:662–673.

52. Alam, S.M., P.J. Travers, J.L. Wung, W. Nasholds, S. Redpath, S.C. Jameson, and N.R. Gascoigne. 1996. T-cell receptor affinity and thymocyte positive selection. Nature (Lond.). 381:616–620.

53. Lyons, D.S., S.A. Lieberman, J. Hampl, J.J. Boniface, P.A. Rey, Y.-h. Chien, L.J. Berg, and M.M. Davis. 1996. A T cell receptor binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity. 5:53–61.
Selective activation of the calcium signaling pathway by altered peptide ligands. J. Exp. Med. 184:1525–1530.
48. Timmerman, L.A., N.A. Clipstone, S.N. Ho, and J.P. Northrop. 1996. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. Nature (Lond.). 383:837–840.
49. Karttunen, J., and N. Shastri. 1991. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. U.S.A. 88:3972–3976.
50. Valitutti, S., M. Dessing, K. Aktories, H. Gallati, and A. Lanzavecchia. 1995. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 181:577–584.